表紙
市場調查報告書

肝臟移植排斥反應:開發中產品分析

Liver Transplant Rejection - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 379062
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
肝臟移植排斥反應:開發中產品分析 Liver Transplant Rejection - Pipeline Review, H1 2020
出版日期: 2020年03月31日內容資訊: 英文 69 Pages
簡介

肝臟移植是在各種肝臟疾病上常進行的治療法。肝臟與其他臟器不同,具有獨特的再生、成長力。肝臟移植是以健康肝臟取代受損、或是有疾病的肝臟,移植整個或部分的肝臟。移植後,免疫系統會視移植的肝臟為異物,而產生排斥反應,患者便容易因此引發併發症。因此要同時服用免疫抑制劑。這個免疫抑制劑的作用,在於防止各種免疫反應造成身體同定或攻擊外部移植器官,防止器官排斥反應,以促進移植成功。

本報告提供肝臟移植排斥反應的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

肝臟移植排斥反應 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關研究中的產品

治療藥的開發企業

  • Astellas Pharma Inc.
  • Biogen Inc
  • Conatus Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • Novartis AG
  • RedHill Biopharma Ltd.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ABC-294640
  • cardiotrophin-1
  • 肝臟移植排斥反應細胞免疫療法
  • Everolimus
  • FX-06
  • reparikishin
  • Rituximab
  • Tacrolimus ER
  • TR-002

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12086IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2020, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.

Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any other organ in the body. Liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Liver Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 2, 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 2, 1 and 1 molecules, respectively.

Liver Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Liver Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Transplant Rejection (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Liver Transplant Rejection - Overview
  • Liver Transplant Rejection - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Liver Transplant Rejection - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Liver Transplant Rejection - Companies Involved in Therapeutics Development
  • Alexion Pharmaceuticals Inc
  • Dompe Farmaceutici SpA
  • F4 Pharma GmbH
  • Helocyte Biosciences Inc
  • Novartis AG
  • Pharmapraxis
  • Quell Therapeutics Ltd
  • TRACT Therapeutics Inc
  • Veloxis Pharmaceuticals AS
  • Liver Transplant Rejection - Drug Profiles
  • Cellular Immunotherapy for Liver Transplant Rejection - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Liver Transplantation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Liver Transplantation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • eculizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FX-06 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • iscalimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • QEL-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • reparixin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tacrolimus ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TR-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tregcel - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Triplex - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Liver Transplant Rejection - Dormant Projects
  • Liver Transplant Rejection - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Liver Transplant Rejection, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Liver Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
  • Liver Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, H1 2020
  • Liver Transplant Rejection - Pipeline by F4 Pharma GmbH, H1 2020
  • Liver Transplant Rejection - Pipeline by Helocyte Biosciences Inc, H1 2020
  • Liver Transplant Rejection - Pipeline by Novartis AG, H1 2020
  • Liver Transplant Rejection - Pipeline by Pharmapraxis, H1 2020
  • Liver Transplant Rejection - Pipeline by Quell Therapeutics Ltd, H1 2020
  • Liver Transplant Rejection - Pipeline by TRACT Therapeutics Inc, H1 2020
  • Liver Transplant Rejection - Pipeline by Veloxis Pharmaceuticals AS, H1 2020
  • Liver Transplant Rejection - Dormant Projects, H1 2020
  • Liver Transplant Rejection - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Liver Transplant Rejection, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020